Growth-hormone secretagogue · Compounded 503A · Subcutaneous
Sermorelin: the GHRH analogue that restores natural GH pulses.
Sermorelin is a 29-amino-acid synthetic fragment of human growth-hormone-releasing hormone (GHRH 1-29) — the smallest sequence retaining full biological activity. It stimulates the pituitary to release endogenous GH in its natural pulsatile pattern, preserving negative-feedback safety not seen with exogenous HGH.
Free shipping over $150 · Pay with card or crypto
What Sermorelin is
Sermorelin is the synthetic 1-29 amino-acid fragment of native GHRH — the smallest sequence that retains full receptor activity. It was originally FDA-approved (Geref, Serono) for pediatric growth-hormone deficiency and later discontinued commercially in 2008 for non-safety reasons.
It is now used off-label in adults as a compounded 503A preparation for age-related GH decline, body composition, sleep quality, and recovery.
Unlike exogenous recombinant HGH, sermorelin works upstream — it asks the pituitary to release the GH it can make. Endogenous negative feedback remains intact, which is the central safety argument over direct HGH.
How it works
GHRH neurons in the arcuate nucleus normally fire in pulses every ~3 hours, with the largest pulse during early slow-wave sleep. Sermorelin amplifies this physiologic pulse.
It binds the GHRH receptor on pituitary somatotrophs, triggering cAMP-mediated synthesis and release of growth hormone. GH then signals the liver and peripheral tissues to produce IGF-1.
Because somatostatin and IGF-1 still inhibit further release, the system self-regulates — high IGF-1 from sermorelin suppresses additional GH release, which is the mechanistic basis for its safety profile relative to direct HGH.
What patients use it for
Improved sleep quality
Most consistent patient-reported benefit. Sermorelin amplifies the early-night GH pulse tied to slow-wave sleep — many patients notice within 2–4 weeks.
Body composition support
Modest reductions in visceral fat and modest gains in lean mass over 3–6 months in adults with age-related GH decline.
Recovery and connective tissue
IGF-1-mediated effects on collagen synthesis support tendon, ligament, and skin recovery — especially in midlife and beyond.
Physiologic safety profile
Preserved negative feedback. Supraphysiologic IGF-1 levels are unusual on monotherapy, and the pituitary will not "release more than it can make."
Evidence summary
Walker RF et al. (Drugs of Today, 1995) reviewed sermorelin pharmacology and adult-deficient growth-hormone restoration data.
Khorram O et al. (J Clin Endocrinol Metab, 1997) demonstrated improved body composition and quality of life in healthy older adults treated with GHRH 1-29 over 16 weeks.
Aimaretti G et al. (J Endocrinol Invest, 2004) reviewed GHRH testing and therapeutic use in adult GH deficiency.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Typical adult protocol: 200–500 mcg subcutaneously at bedtime, 5–7 nights per week. Bedtime dosing aligns with the natural early-sleep GH pulse.
Often paired with ipamorelin or CJC-1295 for synergistic GHRH + GHRP stimulation — the combination produces a larger, cleaner pulse than either alone.
Avoid eating within ~2 hours before injection; high blood glucose blunts GH release. Cycle and duration are individualized — many clinicians use 3–6 month courses with periodic breaks.
Safety and contraindications
Most common side effects: injection-site reactions, transient flushing, mild headache. All typically mild and self-limited.
Contraindications: active malignancy, pregnancy, breastfeeding. Caution in proliferative diabetic retinopathy and severe insulin resistance.
Compounded sermorelin is not FDA-approved as a finished product post-2008 and is used off-label under physician supervision through a licensed 503A pharmacy.
Periodic IGF-1 monitoring is reasonable on extended courses to confirm levels stay within the age-appropriate physiologic range.
Who it's typically considered for
- Healthy adults 35+ with symptoms suggestive of age-related GH decline (poor sleep, slow recovery, body-composition shifts)
- Patients seeking the GH-axis pathway without the risks of exogenous HGH
- Patients combining peptide therapy with strength training, sleep, and metabolic optimization
- Patients who tolerated or partially responded to ipamorelin and want amplified pulse
Frequently asked questions
Sermorelin vs HGH — which is safer?
Sermorelin preserves pituitary negative feedback, so it cannot push IGF-1 to supraphysiologic levels the way unsupervised HGH can. For adults without diagnosed GH deficiency, sermorelin is the more physiologic approach.
How long until I notice results?
Sleep improvements often within 2–4 weeks. Body composition and recovery changes over 8–16 weeks. The peptide works on the body's timeline — there is no rapid-onset effect.
Should I pair sermorelin with ipamorelin or CJC-1295?
GHRH + GHRP combinations (sermorelin + ipamorelin, or CJC-1295 + ipamorelin) produce a larger synergistic GH pulse than either alone. The decision is individualized to goals and tolerance.
Will sermorelin raise IGF-1 like HGH does?
Yes — but typically into the upper end of the age-appropriate physiologic range rather than supraphysiologic. This is by design and reflects the preserved feedback loop.
Is sermorelin banned in sports?
Yes. WADA prohibits all GH secretagogues, including sermorelin. Competitive tested athletes should not use it.
Can women use sermorelin?
Yes. Women in perimenopause and menopause frequently report meaningful sleep, recovery, and skin benefits. Avoid in pregnancy and breastfeeding.
How often do I need lab work?
Baseline IGF-1 is standard. Repeat at ~8–12 weeks to confirm physiologic response and exclude supraphysiologic levels. Periodic monitoring on long courses is reasonable.
Can sermorelin help with weight loss?
GH-axis therapy modestly reduces visceral fat but is not a primary weight-loss tool. For meaningful weight loss, a GLP-1 (semaglutide, tirzepatide) is far more effective.
Sources
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging (2006). — pubmed.ncbi.nlm.nih.gov/18046911
- Khorram O et al. Effects of [Nle27]growth hormone-releasing hormone (1-29)-NH2 in healthy older adults. J Clin Endocrinol Metab (1997). — pubmed.ncbi.nlm.nih.gov/9100591
- Aimaretti G et al. Growth hormone-releasing hormone test in adult GHD. J Endocrinol Invest (2004). — pubmed.ncbi.nlm.nih.gov/15053248
- Vittone J et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism (1997). — pubmed.ncbi.nlm.nih.gov/9225826
Considering Sermorelin?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Related peptides
Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026
Last reviewed July 3, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.